309
Participants
Start Date
December 31, 2011
Primary Completion Date
December 29, 2015
Study Completion Date
December 29, 2015
mipomersen sodium 200 mg
Subcutaneous mipomersen 200 mg once weekly
Placebo
Placebo vehicle for subcutaneous injection.
mipomersen sodium 70 mg
Subcutaneous mipomersen 70 mg thrice weekly
Mission Viejo
Aurora
Cooper City
Winter Park
Indianapolis
Kansas City
Boston
Ann Arbor
Grandville
Rochester
St Louis
Omaha
Summit
North Massapequa
Portland
Lancaster
Charleston
Nashville
Dallas
Norfolk
Buenos Aires
Córdoba
Perth
South Brisbane
Edegem
Haine-Saint-Paul
Leuven
Rio de Janeiro
São Paulo
Chicoutimi
Montreal
Sainte-Foy
Osijek
Zagreb
Hradec Králové
Prague
Aarhus
Viborg
Aachen
Berlin
Cologne
Freiburg im Breisgau
Hamburg
Heidelberg
Magdeburg
Ioannina
Kallithea
Hong Kong
Baja
Budapest
Debrecen
New Delhi
Holon
Kfar Saba
Ofakim
Bologna
Napoli
Padua
Palermo
Pisa
Roma
Kuala Lumpur
Kubang Kerian
Alkmaar
Amsterdam
Maastricht
Nijmegen
Utrecht
Waalwijk
Christchurch
Bodø
Oslo
Sandefjord
Bialystok
Gdansk
Katowice
Krakow
Nałęczów
Poznan
Sopot
Szczecin
Warsaw
Wroclaw
Barnaul
Kemerovo
Moscow
Novosibirsk
Petrozavodsk
Ryazan
Saint Petersburg
Tomsk
Yaroslavl
Cape Town
Pretoria
Seoul
Madrid
Stockholm
New Taipei City
Taipei
Ankara
Istanbul
Izmir
Sivas
Ivano-Frankivsk
Kiev
Kyiv
Odesa
Birmingham
Cardiff
Liverpool
London
Manchester
Oldham
Lead Sponsor
Kastle Therapeutics, LLC
INDUSTRY